Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.47 |
| ▸ | MMP9 | P14780 | 8/20 | 0.47 |
| ▸ | MMP1 | P03956 | 7/20 | 0.45 |
| ▸ | MMP3 | P08254 | 7/20 | 0.45 |
| ▸ | MMP7 | P09237 | 7/20 | 0.45 |
| ▸ | MMP13 | P45452 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186210 | 0.99 | MMP2 (0.47) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3197615 | 0.91 | MMP2 (0.48) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3179868 | 0.87 | MMP2 (0.43) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3188199 | 0.86 | LMNA (0.43) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3188168 | 0.86 | MMP2 (0.47) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3189200 | 0.85 | CA1 (0.56) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3187905 | 0.85 | CA1 (0.56) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3185242 | 0.85 | CA1 (0.56) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL13335258 | 0.85 | CA1 (0.56) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL3194976 | 0.85 | MMP2 (0.46) | MMP2MMP9MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | WYETH (US) | 2007-02-15 | — | — | US | claimed |
| US-7166622-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2007-01-23 | — | — | US | claimed |
| US-20040006050-A1 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2004-01-08 | — | — | US | claimed |
| US-20100120725-A1 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-7671075-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1549306-A4 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-7166622-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1549306-A1 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | Wyeth (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040006050-A1 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003103660-A1 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120725-A1 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | MMP2 2484/4885MMP9 2795/4885MMP1 2585/4885 |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | BACE1, APP, PSEN1 | MMP2 3545/4885MMP9 2856/4885MMP1 3438/4885 |
| US-20040006050-A1 | Substituted phenylsulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | MMP2 2539/4885MMP9 2402/4885MMP1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.